Overall Survival | ||||
---|---|---|---|---|
Univariate | Multivariate | |||
Sex (male vs female) | p = 0.05 | HR 0.24 (0.057 – 1.041) | P = 0.032 | HR 0.176 (0.036 – 0.865) |
COPD (no vs yes) | p = 0.03 | HR 0.20 (0.048 – 0.896) | P = 0.021 | HR 0.15 (0.03 – 0.756) |
Uni x Bilateral | p = 0.26 | HR 0.44 (0.105 – 1.873) | - | |
Age (<45 y vs ≥45 y) | p = 0.77 | HR 1.21 (0.325 – 4.533) | - | |
ZPS pretreatment (0–2 vs 3/4) | p = 0.09 | HR 0.30 (0.72 – 1.243) | - | |
ZPS posttreatment (0–1 vs 2–4) | p = 0.07 | HR 0.27 (0.63 – 1.164) | - | |
Local Failure-Free Survival | ||||
Univariate | Multivariate | |||
Sex (male vs female) | p = 0.42 | HR 0.44 (0.06 – 3.24) | - | |
COPD (no vs yes) | p = 0.94 | HR 1.079 (0.111 – 10.519) | - | |
Uni x Bilateral | p = 0.15 | HR 0.239 (0.033 – 1.718) | - | |
Age (<45 y vs ≥45 y) | p = 0.29 | HR 73.655 (0.023 - >100) | - | |
ZPS pretreatment (0–2 vs 3/4) | p = 0.06 | HR 0.114 (0.012 – 1.117) | - | |
ZPS posttreatment (0–1 vs 2–4) | p = 0.33 | HR 0.006 (<0.001 - >100) | - |